

### Claims

1.-11. (canceled)

12. (currently amended) A substantially pure or isolated stabilized oligodeoxynucleotide of between 18 and 30 nucleotides in length~~The stabilized oligodeoxynucleotide of claim 8~~, comprising any one of

5'-[X<sub>1</sub>X<sub>2</sub>]TGCATCGATGCAGGGGGG -3' (SEQ ID NO:12);  
5'- [X<sub>1</sub>X<sub>2</sub>]TGCACCGGTGCAGGGGGG -3' (SEQ ID NO:13);  
5'- [X<sub>1</sub>X<sub>2</sub>]TGCGTCGACGCAGGGGGG -3' (SEQ ID NO:14);  
5'- [X<sub>1</sub>X<sub>2</sub>]TGCGCCGGCGCAGGGGGG -3' (SEQ ID NO:17);  
5'- GGTGCATCGATGCAGGGGGG -3' (SEQ ID NO: 1);  
5'- GGTGCGTCGACGCAGGGGGG -3' (SEQ ID NO: 31);  
5'- GGTGCACCGGTGCAGGGGGG -3' (SEQ ID NO: 2); or,  
5'- GGTGCATCGATGCAGGGGGG -3' (SEQ ID NO: 73).

13. (currently amended) The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the oligodeoxynucleotide is modified to prevent degradation.

14. (currently amended) The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the oligodeoxynucleotide has a phosphate backbone modification.

15. (previously presented) The stabilized oligodeoxynucleotide of claim 14, wherein the phosphate backbone modification is a phosphorothioate backbone modification.

16.-18. (canceled)

19. (currently amended) An oligodeoxynucleotide delivery complex comprising the stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, and a targeting moiety.

20. (previously presented) The stabilized oligodeoxynucleotide delivery complex of claim 19, wherein the targeting moiety is selected from the group consisting of a cholesterol, a virosome, a liposome, a lipid, and a target cell specific binding agent.

21. **(previously presented)** The oligodeoxynucleotide delivery complex of claim 19, wherein the stabilized oligodeoxynucleotide and the targeting moiety are covalently linked.

22. **(currently amended)** A pharmacological composition comprising the stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, and a pharmacologically acceptable carrier.

23.-60. **(canceled)**

61. **(currently amended)** The stabilized oligodeoxynucleotide of claim ~~[[8]]~~12, wherein the stabilized oligonucleotide comprises at least one~~Pu<sub>1</sub>Py<sub>2</sub>CpG-Pu<sub>3</sub>Py<sub>4</sub>comprise~~ phosphodiester base[[s]].

62. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide comprises a plurality of~~Pu<sub>1</sub>Py<sub>2</sub>CpG-Pu<sub>3</sub>Py<sub>4</sub>are~~ phosphodiester bases.

63. **(canceled)**

64. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide~~X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>~~ comprises one or more phosphorothioate bases.

65. **(currently amended)** The stabilized oligodeoxynucleotide of claim 61, wherein the stabilized oligonucleotide~~X<sub>4</sub>X<sub>5</sub>X<sub>6</sub>(W)<sub>M</sub>(G)<sub>N</sub>~~ comprises a plurality of~~one or more~~ phosphorothioate bases.

66. **(Canceled)**

67. **(currently amended)** The stabilized oligodeoxynucleotide of claim ~~[[66]]~~12, further comprising at least one additional G in the 5' far flanking region.